FDMT
Price
$12.99Alerts
Change
+$0.53 (+4.25%)
Updated
Nov 11 closing price
Capitalization
676.74M
107 days until earnings call
Intraday BUY SELL Signals
GHRS
Price
$19.25Alerts
Change
-$0.31 (-1.58%)
Updated
Nov 11 closing price
Capitalization
1.28B
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FDMT vs GHRS

FDMT vs GHRS Comparison Chart in %
View a ticker or compare two or three
VS
FDMT vs. GHRS commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FDMT is a Buy and GHRS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for FDMT with price predictions
Nov 10, 2026

FDMT's RSI Indicator ascending out of oversold territory

The RSI Indicator for FDMT moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 26 of the 28 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 57 cases where FDMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FDMT as a result. In 75 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for FDMT just turned positive on October 29, 2026. Looking at past instances where FDMT's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.

Following a +10.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in 217 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

FDMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for FDMT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for FDMT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.660) is normal, around the industry mean (3.498). P/E Ratio (-4.658) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.662) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for GHRS with price predictions
Nov 10, 2026

GHRS in +5.10% Uptrend, advancing for three consecutive days on November 10, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GHRS advanced for three days, in 249 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GHRS's RSI Oscillator exited the oversold zone, 16 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for GHRS just turned positive on October 23, 2026. Looking at past instances where GHRS's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GHRS as a result. In 88 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

GHRS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GHRS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.553) is normal, around the industry mean (3.498). P/E Ratio (-18.798) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. GHRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
FDMT: Fundamental Ratings
FDMT
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
48
P/E GROWTH RATING
1..100
59
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FDMTGHRS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 2 days ago
89%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (FDMT: $12.46 vs. GHRS: $19.56)
Brand notoriety: FDMT and GHRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FDMT: 105% vs. GHRS: 26%
Market capitalization -- FDMT: $676.74M vs. GHRS: $1.28B
FDMT [@Biotechnology] is valued at $676.74M. GHRS’s [@Biotechnology] market capitalization is $1.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FDMT’s FA Score shows that 1 FA rating(s) are green while GHRS’s FA Score has 2 green FA rating(s).

  • FDMT’s FA Score: 1 green, 4 red.
  • GHRS’s FA Score: 2 green, 3 red.
According to our system of comparison, both FDMT and GHRS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FDMT’s TA Score shows that 6 TA indicator(s) are bullish while GHRS’s TA Score has 4 bullish TA indicator(s).

  • FDMT’s TA Score: 6 bullish, 3 bearish.
  • GHRS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, FDMT is a better buy in the short-term than GHRS.

Price Growth

FDMT (@Biotechnology) experienced а +4.27% price change this week, while GHRS (@Biotechnology) price change was -3.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.

Reported Earning Dates

FDMT is expected to report earnings on Feb 26, 2027.

GHRS is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

FDMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, FDMT has been loosely correlated with KYTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if FDMT jumps, then KYTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FDMT
1D Price
Change %
FDMT100%
-0.16%
KYTX - FDMT
59%
Loosely correlated
-1.74%
RCKT - FDMT
55%
Loosely correlated
-3.16%
PRME - FDMT
54%
Loosely correlated
-9.30%
EDIT - FDMT
54%
Loosely correlated
-8.91%
SLDB - FDMT
53%
Loosely correlated
+2.14%
More

GHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GHRS has been loosely correlated with STTK. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if GHRS jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GHRS
1D Price
Change %
GHRS100%
+1.56%
STTK - GHRS
44%
Loosely correlated
-2.81%
FDMT - GHRS
40%
Loosely correlated
-0.16%
IMRX - GHRS
39%
Loosely correlated
+5.48%
VIR - GHRS
38%
Loosely correlated
-3.63%
SANA - GHRS
37%
Loosely correlated
-1.42%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LAKE9.260.26
+2.89%
Lakeland Industries
LIMN2.770.07
+2.59%
Liminatus Pharma Inc
AEXA10.610.01
+0.09%
American Exceptionalism Acquisition Corp A
STRC99.89-0.04
-0.04%
Strategy Inc Variable Rate Series A Perpetual Stretch Preferred Stock
TOL152.19-4.14
-2.65%
Toll Brothers